- Home
- NYXH vs NTHI Comparison
NYXH vs NTHI Comparison
Compare NYXH & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NYXH | NTHI |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.1M | 193.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NYXH | NTHI |
|---|---|---|
| Price | $4.86 | $9.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.67 | N/A |
| AVG Volume (30 Days) | 50.6K | ★ 54.4K |
| Earning Date | 03-12-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,616,215.00 | $59,990.00 |
| Revenue This Year | $75.27 | N/A |
| Revenue Next Year | $277.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.96 | N/A |
| 52 Week Low | $4.35 | $3.20 |
| 52 Week High | $11.87 | $25.00 |
Technical Indicators
Market Signals| Indicator | NYXH | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 58.52 |
| Support Level | $4.70 | $8.51 |
| Resistance Level | $5.00 | $10.19 |
| Average True Range (ATR) | 0.22 | 0.81 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 36.30 | 64.34 |
Price Performance
Historical ComparisonAbout NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).